Clinical trial
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast…
NCT00368875 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00368875 |
|---|---|
| Title | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer |
| Official title | Phase I/II Study of a Combination of Suberoylanilide Hydroxamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | vorinostat, paclitaxel, bevacizumab |
| Enrollment | 54 |
| Start date | Jul 1, 2006 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Aug 29, 2006 |
| Last update posted | Nov 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: